Skip to main content

Find a clinical trial

IJB_2672

A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older Mickael Aoun

CANFOUR

An open label, dose escalation followed by dose expansion, safety and tolerability trial of CAN04, a fully humanized monoclonal antibody against IL1RAP, in subjects with solid malignant tumors Christiane Jungels

Apple

APPLE trial: Feasibility and activity of AZD9291 (osimertinib) treatment on Positive PLasma T790M in EGFR mutant NSCLC patients Thierry Berghmans

INCB59872-101

A Phase 1/2, Open-Label, Dose-Escalation / Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies Ahmad Hussein Awada

IJB_2732

A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination with Anti-PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors Nuria Kotecki

INCAGN1876-201

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies Philippe Aftimos

LUNAR

Ancient Title : LUNAR: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) in combination with PD-1 inhibitors or docetaxel, for second line treatment of non-small cell lung cancer (NSCLC).- New Title : LUNAR: Pivotal, randomized, open-label study of Tumor Treating Fields(TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure (avis 09/04/19) Thierry Berghmans

Nivothym

Single-arm, multicenter, phase II study of nivolumab in patients with type B3 thymoma and thymic carcinoma previously treated with chemotherapy - (Nivothym) Thierry Berghmans

OX2016-203-01

An open-label, dose-escalation, phase I study to assess the safety, pharmacokinetics and pharmacodynamics of AsiDNA, a DNA repair inhibitor administered intravenously in patients with advanced solid tumors Nuria Kotecki

SPECTA

SPECTA : Screening Cancer Patients for Efficient Clinical Trial Access Thierry Berghmans

ETOP 12-17 ALERT-lung

A single arm phase II trial evaluating the activity of alectinib for the treatment of pretreated RET-rearranged advanced NSCLC (ETOP 12-17 ALERT-lung) Thierry Berghmans

EORTC 1658

Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD) Konstantinos Stathopoulos

B079201215796

Role of bronchoscopy assisted by electromagnetic navigation (EMN) in the diagnosis of small pulmonary nodules of indeterminate nature. A prospective study by the European Lung Cancer Working Party Thierry Berghmans

I3Y-MC-JPBO

A phase II study of Abemaciclib in patients with brain metastases secondary to hormone receptor positive breast cancer, non-small cell lung cancer, or melanoma Ahmad Hussein Awada

1367.1

An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit Ahmad Hussein Awada

B079201523324

Does inflammation have a significant implication in Lung Cancer evolution? Anne-Pascale Meert

PM1183-B-005-14

A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors Ahmad Hussein Awada

D5164C00001 ADAURA

A Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA) Thierry Berghmans

PEARLS

A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS) Thierry Berghmans

I7W-MC-JQBA

A Phase 1 Study of LY3127804 as Monotherapy and in Combination with Ramucirumab in Patients with Advanced Solid Tumors Ahmad Hussein Awada